Kelly Maloney
Concepts (352)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 36 | 2023 | 280 | 5.820 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 16 | 2022 | 1438 | 1.570 |
Why?
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 9 | 2023 | 62 | 1.520 |
Why?
| Down Syndrome | 5 | 2019 | 361 | 1.510 |
Why?
| Asparaginase | 8 | 2020 | 30 | 1.010 |
Why?
| Burkitt Lymphoma | 2 | 2020 | 54 | 0.880 |
Why?
| Consolidation Chemotherapy | 2 | 2019 | 9 | 0.790 |
Why?
| Child | 64 | 2023 | 19282 | 0.790 |
Why?
| Leukemia, Myeloid, Acute | 5 | 2022 | 529 | 0.760 |
Why?
| Child, Preschool | 44 | 2023 | 9776 | 0.660 |
Why?
| Leukemia | 4 | 2021 | 212 | 0.650 |
Why?
| Mercaptopurine | 5 | 2017 | 16 | 0.610 |
Why?
| Oncogene Proteins, Fusion | 5 | 2021 | 205 | 0.570 |
Why?
| Disease-Free Survival | 10 | 2022 | 678 | 0.550 |
Why?
| Antineoplastic Agents | 7 | 2019 | 2017 | 0.550 |
Why?
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 | 2016 | 93 | 0.540 |
Why?
| Preleukemia | 1 | 2015 | 2 | 0.540 |
Why?
| Neoplasm Recurrence, Local | 3 | 2021 | 884 | 0.530 |
Why?
| Drug Hypersensitivity | 3 | 2017 | 83 | 0.520 |
Why?
| Molecular Targeted Therapy | 3 | 2021 | 373 | 0.510 |
Why?
| Leukemia, Monocytic, Acute | 1 | 2014 | 4 | 0.510 |
Why?
| Sarcoma, Myeloid | 1 | 2014 | 4 | 0.510 |
Why?
| Prognosis | 13 | 2021 | 3603 | 0.480 |
Why?
| Bone Marrow Transplantation | 1 | 2014 | 261 | 0.460 |
Why?
| Infant | 31 | 2023 | 8440 | 0.450 |
Why?
| Acute Kidney Injury | 1 | 2019 | 651 | 0.450 |
Why?
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2023 | 18 | 0.440 |
Why?
| Neoplasm, Residual | 6 | 2021 | 99 | 0.440 |
Why?
| Erwinia | 2 | 2020 | 3 | 0.430 |
Why?
| Tumor Suppressor Proteins | 3 | 1999 | 302 | 0.420 |
Why?
| Chromosome Aberrations | 2 | 2022 | 136 | 0.420 |
Why?
| Adolescent | 36 | 2023 | 19126 | 0.410 |
Why?
| Neutropenia | 2 | 2022 | 131 | 0.410 |
Why?
| Hematopoietic Stem Cell Transplantation | 2 | 2019 | 542 | 0.410 |
Why?
| Stem Cell Transplantation | 3 | 2019 | 153 | 0.390 |
Why?
| Humans | 76 | 2023 | 121869 | 0.390 |
Why?
| Male | 53 | 2023 | 60475 | 0.390 |
Why?
| Lymphoma, Large B-Cell, Diffuse | 2 | 2022 | 89 | 0.390 |
Why?
| Rhabdomyosarcoma | 1 | 2011 | 61 | 0.380 |
Why?
| Sarcoma, Ewing | 1 | 2011 | 71 | 0.380 |
Why?
| Cell Cycle Proteins | 3 | 1999 | 576 | 0.380 |
Why?
| Carrier Proteins | 3 | 1999 | 740 | 0.370 |
Why?
| Ploidies | 2 | 2019 | 19 | 0.360 |
Why?
| Recurrence | 8 | 2022 | 1002 | 0.360 |
Why?
| Catheter-Related Infections | 2 | 2022 | 67 | 0.350 |
Why?
| Core Binding Factor Alpha 2 Subunit | 3 | 2021 | 29 | 0.340 |
Why?
| Cyclophosphamide | 4 | 2019 | 225 | 0.340 |
Why?
| Genes, Tumor Suppressor | 2 | 1999 | 82 | 0.340 |
Why?
| Catheterization, Central Venous | 2 | 2022 | 96 | 0.330 |
Why?
| Philadelphia Chromosome | 2 | 2018 | 15 | 0.320 |
Why?
| Female | 50 | 2023 | 63903 | 0.320 |
Why?
| Survival Rate | 7 | 2021 | 1828 | 0.300 |
Why?
| Vincristine | 4 | 2021 | 101 | 0.290 |
Why?
| Gene Deletion | 2 | 1998 | 361 | 0.290 |
Why?
| Medication Adherence | 3 | 2017 | 573 | 0.290 |
Why?
| Trisomy | 2 | 2021 | 67 | 0.290 |
Why?
| Antimetabolites, Antineoplastic | 2 | 2017 | 83 | 0.280 |
Why?
| Etoposide | 2 | 2019 | 159 | 0.280 |
Why?
| Neoplasm Proteins | 2 | 2018 | 414 | 0.280 |
Why?
| Anxiety | 3 | 2016 | 873 | 0.250 |
Why?
| Cyclin-Dependent Kinase Inhibitor p16 | 3 | 1999 | 66 | 0.250 |
Why?
| Treatment Outcome | 11 | 2022 | 9654 | 0.230 |
Why?
| Young Adult | 13 | 2023 | 11223 | 0.230 |
Why?
| Medical Oncology | 4 | 2022 | 229 | 0.230 |
Why?
| Gene Rearrangement | 3 | 2019 | 157 | 0.220 |
Why?
| Polyethylene Glycols | 5 | 2020 | 567 | 0.220 |
Why?
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2023 | 58 | 0.220 |
Why?
| Leukemia, Myelomonocytic, Juvenile | 1 | 2022 | 2 | 0.220 |
Why?
| Induction Chemotherapy | 2 | 2019 | 58 | 0.220 |
Why?
| Central Venous Catheters | 1 | 2022 | 40 | 0.210 |
Why?
| Doxorubicin | 2 | 2022 | 312 | 0.210 |
Why?
| Lymphoma | 1 | 2023 | 185 | 0.210 |
Why?
| Prednisone | 2 | 2019 | 239 | 0.200 |
Why?
| Program Evaluation | 2 | 2017 | 876 | 0.200 |
Why?
| Lung Neoplasms | 1 | 2014 | 2237 | 0.200 |
Why?
| Adult | 21 | 2023 | 32683 | 0.200 |
Why?
| Translocation, Genetic | 2 | 2013 | 92 | 0.190 |
Why?
| Maintenance Chemotherapy | 2 | 2017 | 24 | 0.190 |
Why?
| Bacterial Infections | 1 | 2022 | 228 | 0.190 |
Why?
| Polymorphism, Single Nucleotide | 3 | 2017 | 2107 | 0.190 |
Why?
| Risk Factors | 11 | 2022 | 9419 | 0.180 |
Why?
| Diploidy | 1 | 2019 | 14 | 0.180 |
Why?
| Immunocompromised Host | 1 | 2021 | 209 | 0.180 |
Why?
| Genes, p16 | 1 | 1999 | 20 | 0.180 |
Why?
| Antibodies, Bispecific | 1 | 2019 | 30 | 0.180 |
Why?
| Hyperglycemia | 1 | 2023 | 325 | 0.180 |
Why?
| Prospective Studies | 9 | 2022 | 6629 | 0.170 |
Why?
| PAX5 Transcription Factor | 1 | 2019 | 27 | 0.170 |
Why?
| Myelodysplastic Syndromes | 1 | 2020 | 111 | 0.170 |
Why?
| Chromosomes, Human, Pair 19 | 1 | 1998 | 27 | 0.170 |
Why?
| Chromosomes, Human, Pair 17 | 1 | 1998 | 63 | 0.170 |
Why?
| Rituximab | 1 | 2019 | 158 | 0.170 |
Why?
| Mutagenesis | 1 | 1999 | 182 | 0.170 |
Why?
| Chromosomes, Human, Pair 1 | 1 | 1998 | 76 | 0.170 |
Why?
| Patient Safety | 1 | 2021 | 308 | 0.160 |
Why?
| Prostate-Specific Antigen | 2 | 2009 | 173 | 0.160 |
Why?
| Quality of Life | 2 | 2021 | 2453 | 0.160 |
Why?
| Substance Withdrawal Syndrome | 1 | 2020 | 184 | 0.160 |
Why?
| Proto-Oncogenes | 1 | 1997 | 28 | 0.160 |
Why?
| Oncologists | 1 | 2017 | 29 | 0.160 |
Why?
| Thionucleotides | 1 | 2017 | 34 | 0.160 |
Why?
| Thioguanine | 1 | 2017 | 21 | 0.150 |
Why?
| Apyrase | 1 | 2017 | 15 | 0.150 |
Why?
| Family Relations | 2 | 2016 | 90 | 0.150 |
Why?
| Blast Crisis | 1 | 2016 | 19 | 0.150 |
Why?
| Follow-Up Studies | 6 | 2021 | 4883 | 0.150 |
Why?
| Carboxypeptidases A | 1 | 2016 | 2 | 0.150 |
Why?
| Retrospective Studies | 9 | 2023 | 13063 | 0.150 |
Why?
| Sepsis | 1 | 2022 | 493 | 0.140 |
Why?
| Depression | 2 | 2016 | 1201 | 0.140 |
Why?
| Pediatricians | 1 | 2017 | 115 | 0.140 |
Why?
| Genomics | 2 | 2022 | 687 | 0.140 |
Why?
| Mentors | 2 | 2017 | 164 | 0.140 |
Why?
| Osteonecrosis | 1 | 2015 | 21 | 0.140 |
Why?
| Mentoring | 1 | 2017 | 105 | 0.140 |
Why?
| Gene Expression Regulation, Enzymologic | 1 | 2017 | 300 | 0.140 |
Why?
| Nausea | 1 | 2016 | 109 | 0.140 |
Why?
| Central Nervous System Neoplasms | 1 | 2017 | 125 | 0.140 |
Why?
| Adrenal Cortex Hormones | 1 | 2019 | 525 | 0.130 |
Why?
| Pancreatitis | 1 | 2016 | 110 | 0.130 |
Why?
| Longitudinal Studies | 7 | 2016 | 2652 | 0.130 |
Why?
| Dexamethasone | 4 | 2021 | 313 | 0.130 |
Why?
| Mutation | 4 | 2022 | 3520 | 0.130 |
Why?
| Fusion Proteins, bcr-abl | 2 | 2016 | 61 | 0.130 |
Why?
| Bacteremia | 1 | 2016 | 164 | 0.130 |
Why?
| Cyclin-Dependent Kinase Inhibitor p15 | 3 | 1999 | 14 | 0.130 |
Why?
| Monitoring, Physiologic | 1 | 2017 | 285 | 0.130 |
Why?
| High-Throughput Nucleotide Sequencing | 1 | 2017 | 468 | 0.130 |
Why?
| Myeloid-Lymphoid Leukemia Protein | 2 | 2010 | 66 | 0.130 |
Why?
| Antigens, CD | 1 | 2017 | 468 | 0.130 |
Why?
| Flow Cytometry | 1 | 2018 | 1108 | 0.120 |
Why?
| Cross Infection | 1 | 2016 | 221 | 0.120 |
Why?
| Repressor Proteins | 1 | 1997 | 393 | 0.120 |
Why?
| Histone-Lysine N-Methyltransferase | 2 | 2010 | 99 | 0.120 |
Why?
| Immunotherapy | 1 | 2018 | 493 | 0.120 |
Why?
| Pediatrics | 3 | 2021 | 1002 | 0.120 |
Why?
| Chromosomes, Human, Pair 21 | 1 | 2013 | 32 | 0.120 |
Why?
| Life Change Events | 1 | 2014 | 142 | 0.120 |
Why?
| Venous Thromboembolism | 1 | 2017 | 235 | 0.120 |
Why?
| Quality Improvement | 1 | 2021 | 996 | 0.120 |
Why?
| DNA-Binding Proteins | 2 | 1998 | 1392 | 0.120 |
Why?
| Leukemia, Megakaryoblastic, Acute | 1 | 2012 | 8 | 0.110 |
Why?
| Self Report | 1 | 2017 | 740 | 0.110 |
Why?
| Karyotyping | 3 | 2019 | 105 | 0.110 |
Why?
| Myeloproliferative Disorders | 1 | 2012 | 26 | 0.110 |
Why?
| Transcription Factors | 2 | 1998 | 1629 | 0.110 |
Why?
| Arabinonucleosides | 1 | 2011 | 8 | 0.110 |
Why?
| Adenine Nucleotides | 1 | 2011 | 20 | 0.110 |
Why?
| Contraindications | 1 | 2012 | 100 | 0.110 |
Why?
| Antibodies, Monoclonal | 1 | 2018 | 1289 | 0.100 |
Why?
| Cohort Studies | 5 | 2021 | 5300 | 0.100 |
Why?
| Prostatic Neoplasms | 2 | 2009 | 1024 | 0.100 |
Why?
| Chromosomes, Human, Pair 4 | 1 | 2010 | 33 | 0.100 |
Why?
| Chromosomes, Human, Pair 10 | 1 | 2010 | 20 | 0.100 |
Why?
| Pain | 1 | 2016 | 745 | 0.090 |
Why?
| T-Lymphocytes | 1 | 2018 | 1796 | 0.090 |
Why?
| Multivariate Analysis | 4 | 2015 | 1574 | 0.090 |
Why?
| Parents | 2 | 2016 | 1255 | 0.090 |
Why?
| Age Factors | 8 | 2019 | 3173 | 0.090 |
Why?
| Prostatectomy | 1 | 2009 | 111 | 0.090 |
Why?
| Bloom Syndrome | 1 | 1988 | 1 | 0.090 |
Why?
| Neoplasm Metastasis | 1 | 2011 | 591 | 0.080 |
Why?
| Juxtaglomerular Apparatus | 1 | 2007 | 1 | 0.080 |
Why?
| Gene Expression Regulation, Leukemic | 2 | 2016 | 49 | 0.080 |
Why?
| Polymerase Chain Reaction | 1 | 2010 | 1033 | 0.080 |
Why?
| Blood Coagulation | 1 | 2008 | 234 | 0.070 |
Why?
| Drug Administration Schedule | 2 | 2017 | 770 | 0.070 |
Why?
| Stress, Psychological | 1 | 2014 | 1067 | 0.070 |
Why?
| Methotrexate | 2 | 2017 | 236 | 0.070 |
Why?
| Remission Induction | 2 | 2019 | 255 | 0.070 |
Why?
| Drug Monitoring | 2 | 2017 | 188 | 0.070 |
Why?
| Acute Disease | 2 | 2019 | 986 | 0.060 |
Why?
| Personal Satisfaction | 2 | 2017 | 190 | 0.060 |
Why?
| Administration, Oral | 2 | 2017 | 793 | 0.060 |
Why?
| Kidney Neoplasms | 1 | 2007 | 342 | 0.060 |
Why?
| Genetic Variation | 1 | 1988 | 961 | 0.060 |
Why?
| Randomized Controlled Trials as Topic | 2 | 2020 | 1254 | 0.060 |
Why?
| Disease Progression | 2 | 2021 | 2582 | 0.060 |
Why?
| Proto-Oncogene Proteins c-cbl | 1 | 2022 | 12 | 0.050 |
Why?
| Risk | 5 | 2023 | 925 | 0.050 |
Why?
| Transcriptome | 2 | 2019 | 783 | 0.050 |
Why?
| Incidence | 2 | 2019 | 2520 | 0.050 |
Why?
| Drug Therapy | 1 | 2021 | 73 | 0.050 |
Why?
| Exome | 1 | 2022 | 226 | 0.050 |
Why?
| Diarrhea | 2 | 1999 | 180 | 0.050 |
Why?
| Bone Marrow | 1 | 2022 | 259 | 0.050 |
Why?
| Risk Assessment | 3 | 2017 | 3248 | 0.050 |
Why?
| Surveys and Questionnaires | 3 | 2017 | 4922 | 0.050 |
Why?
| Endocrine Glands | 1 | 1979 | 16 | 0.050 |
Why?
| Blood Cell Count | 1 | 1999 | 62 | 0.050 |
Why?
| Viral Load | 1 | 2021 | 432 | 0.050 |
Why?
| Chromosomes, Human | 1 | 2019 | 43 | 0.050 |
Why?
| Azacitidine | 1 | 2020 | 116 | 0.040 |
Why?
| Loss of Heterozygosity | 1 | 1999 | 38 | 0.040 |
Why?
| Cytogenetic Analysis | 1 | 2019 | 27 | 0.040 |
Why?
| Mosaicism | 1 | 2019 | 59 | 0.040 |
Why?
| Interviews as Topic | 1 | 2021 | 604 | 0.040 |
Why?
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2020 | 170 | 0.040 |
Why?
| Genome-Wide Association Study | 2 | 2016 | 1355 | 0.040 |
Why?
| Disinfectants | 1 | 1999 | 35 | 0.040 |
Why?
| Infant, Newborn | 4 | 2019 | 5336 | 0.040 |
Why?
| Sequence Deletion | 1 | 1999 | 178 | 0.040 |
Why?
| Chromosomes | 1 | 2019 | 89 | 0.040 |
Why?
| National Cancer Institute (U.S.) | 1 | 2018 | 42 | 0.040 |
Why?
| United States | 4 | 2021 | 13209 | 0.040 |
Why?
| Overweight | 1 | 2023 | 544 | 0.040 |
Why?
| Escherichia coli O157 | 1 | 1998 | 32 | 0.040 |
Why?
| Hypertension | 1 | 2007 | 1241 | 0.040 |
Why?
| Methylation | 1 | 1998 | 215 | 0.040 |
Why?
| Feasibility Studies | 1 | 2021 | 779 | 0.040 |
Why?
| Community Participation | 1 | 1999 | 126 | 0.040 |
Why?
| Erythrocyte Count | 1 | 2017 | 20 | 0.040 |
Why?
| Family | 1 | 2021 | 596 | 0.040 |
Why?
| Public Health Surveillance | 1 | 2017 | 63 | 0.040 |
Why?
| Food-Drug Interactions | 1 | 2017 | 6 | 0.040 |
Why?
| Leucovorin | 1 | 2017 | 46 | 0.040 |
Why?
| Glucose | 1 | 2023 | 962 | 0.040 |
Why?
| Escherichia coli Infections | 1 | 1998 | 113 | 0.040 |
Why?
| Injections, Intramuscular | 1 | 2017 | 127 | 0.040 |
Why?
| Biopsy | 1 | 2021 | 1090 | 0.040 |
Why?
| Water Purification | 1 | 1999 | 115 | 0.040 |
Why?
| Career Mobility | 1 | 2017 | 72 | 0.040 |
Why?
| Proto-Oncogene Proteins c-ets | 1 | 1997 | 57 | 0.040 |
Why?
| Genetic Predisposition to Disease | 2 | 2017 | 2377 | 0.040 |
Why?
| Dairy Products | 1 | 2017 | 30 | 0.040 |
Why?
| Qualitative Research | 1 | 2021 | 891 | 0.040 |
Why?
| Cranial Irradiation | 1 | 2017 | 64 | 0.040 |
Why?
| Cerebrospinal Fluid | 1 | 2017 | 92 | 0.040 |
Why?
| Sulfonamides | 1 | 2020 | 458 | 0.040 |
Why?
| MEF2 Transcription Factors | 1 | 2016 | 59 | 0.040 |
Why?
| Infusions, Intravenous | 1 | 2017 | 387 | 0.040 |
Why?
| Methyltransferases | 1 | 2017 | 63 | 0.040 |
Why?
| Leukocyte Count | 1 | 2017 | 319 | 0.040 |
Why?
| NIH 3T3 Cells | 1 | 2016 | 142 | 0.040 |
Why?
| Luciferases | 1 | 2016 | 152 | 0.040 |
Why?
| Middle Aged | 10 | 2019 | 28961 | 0.040 |
Why?
| Methyl Ethers | 1 | 1996 | 8 | 0.040 |
Why?
| Anesthetics, Inhalation | 1 | 1996 | 15 | 0.040 |
Why?
| Ethers | 1 | 1996 | 18 | 0.040 |
Why?
| Breast Neoplasms | 5 | 1979 | 1970 | 0.040 |
Why?
| Bone Morphogenetic Protein 7 | 1 | 2015 | 10 | 0.040 |
Why?
| Fluorides | 1 | 1996 | 50 | 0.040 |
Why?
| Cytarabine | 1 | 2016 | 58 | 0.030 |
Why?
| Health Education | 1 | 1999 | 328 | 0.030 |
Why?
| Alternative Splicing | 1 | 2017 | 202 | 0.030 |
Why?
| Genotype | 3 | 2017 | 1952 | 0.030 |
Why?
| Severity of Illness Index | 2 | 2017 | 2876 | 0.030 |
Why?
| Histone Deacetylase Inhibitors | 1 | 2016 | 206 | 0.030 |
Why?
| Disease Management | 1 | 2019 | 608 | 0.030 |
Why?
| DNA Methylation | 1 | 1999 | 496 | 0.030 |
Why?
| Homeodomain Proteins | 1 | 1998 | 490 | 0.030 |
Why?
| Intensive Care Units, Pediatric | 1 | 2016 | 208 | 0.030 |
Why?
| HEK293 Cells | 1 | 2017 | 655 | 0.030 |
Why?
| Biomarkers, Tumor | 1 | 2021 | 1075 | 0.030 |
Why?
| Aged | 9 | 2019 | 20705 | 0.030 |
Why?
| Promoter Regions, Genetic | 1 | 1999 | 1211 | 0.030 |
Why?
| Sequence Analysis, RNA | 1 | 2016 | 425 | 0.030 |
Why?
| Income | 1 | 2014 | 178 | 0.030 |
Why?
| Blood Glucose | 1 | 2023 | 1949 | 0.030 |
Why?
| Algorithms | 1 | 2021 | 1618 | 0.030 |
Why?
| Demography | 1 | 2014 | 286 | 0.030 |
Why?
| Marriage | 1 | 2014 | 114 | 0.030 |
Why?
| Behavior | 1 | 2014 | 103 | 0.030 |
Why?
| Psychomotor Agitation | 1 | 2014 | 79 | 0.030 |
Why?
| Base Sequence | 1 | 2016 | 2217 | 0.030 |
Why?
| Case-Control Studies | 2 | 2016 | 3314 | 0.030 |
Why?
| Clinical Trials as Topic | 1 | 2017 | 1012 | 0.030 |
Why?
| In Situ Hybridization, Fluorescence | 1 | 2013 | 332 | 0.030 |
Why?
| Odds Ratio | 1 | 2015 | 1052 | 0.030 |
Why?
| Nucleoside Transport Proteins | 1 | 2011 | 4 | 0.030 |
Why?
| Aggression | 1 | 2014 | 201 | 0.030 |
Why?
| Erythrocytes | 1 | 2017 | 633 | 0.030 |
Why?
| Antineoplastic Agents, Alkylating | 1 | 2011 | 70 | 0.030 |
Why?
| Regression Analysis | 1 | 2014 | 1049 | 0.030 |
Why?
| Escherichia coli | 1 | 2015 | 791 | 0.030 |
Why?
| Time Factors | 2 | 2015 | 6889 | 0.030 |
Why?
| Mice | 2 | 2019 | 15621 | 0.030 |
Why?
| Antineoplastic Agents, Phytogenic | 1 | 2011 | 191 | 0.020 |
Why?
| Bacteria | 1 | 2016 | 764 | 0.020 |
Why?
| Survival Analysis | 1 | 2013 | 1356 | 0.020 |
Why?
| Logistic Models | 1 | 2015 | 2037 | 0.020 |
Why?
| Obesity | 1 | 2023 | 2802 | 0.020 |
Why?
| Prevalence | 1 | 2016 | 2444 | 0.020 |
Why?
| Mice, Inbred C57BL | 1 | 2019 | 5054 | 0.020 |
Why?
| Kaplan-Meier Estimate | 1 | 2011 | 901 | 0.020 |
Why?
| Sister Chromatid Exchange | 1 | 1988 | 4 | 0.020 |
Why?
| Genetic Complementation Test | 1 | 1988 | 64 | 0.020 |
Why?
| Cell Fusion | 1 | 1988 | 52 | 0.020 |
Why?
| Emotions | 1 | 2014 | 530 | 0.020 |
Why?
| Protein C | 1 | 2008 | 38 | 0.020 |
Why?
| Antithrombins | 1 | 2008 | 57 | 0.020 |
Why?
| Water Microbiology | 2 | 1999 | 79 | 0.020 |
Why?
| Plasminogen Activator Inhibitor 1 | 1 | 2008 | 93 | 0.020 |
Why?
| Fibrinogen | 1 | 2008 | 167 | 0.020 |
Why?
| Genetic Markers | 1 | 1988 | 371 | 0.020 |
Why?
| Biomarkers | 1 | 2017 | 3652 | 0.020 |
Why?
| Renin-Angiotensin System | 1 | 2007 | 84 | 0.020 |
Why?
| Biopsy, Needle | 1 | 2007 | 189 | 0.020 |
Why?
| Transplantation, Homologous | 1 | 2008 | 450 | 0.020 |
Why?
| Blood Pressure Determination | 1 | 2007 | 137 | 0.020 |
Why?
| Rare Diseases | 1 | 2007 | 109 | 0.020 |
Why?
| Nephrectomy | 1 | 2007 | 158 | 0.020 |
Why?
| Animals | 2 | 2019 | 34134 | 0.020 |
Why?
| RNA, Messenger | 1 | 2011 | 2746 | 0.010 |
Why?
| Immunohistochemistry | 1 | 2007 | 1738 | 0.010 |
Why?
| Cell Line | 1 | 1988 | 2815 | 0.010 |
Why?
| Estriol | 1 | 1979 | 6 | 0.010 |
Why?
| Menstruation | 1 | 1979 | 35 | 0.010 |
Why?
| Estrone | 1 | 1979 | 34 | 0.010 |
Why?
| Prolactin | 1 | 1979 | 101 | 0.010 |
Why?
| Bolivia | 1 | 1999 | 59 | 0.010 |
Why?
| Luteinizing Hormone | 1 | 1979 | 181 | 0.010 |
Why?
| Follicle Stimulating Hormone | 1 | 1979 | 220 | 0.010 |
Why?
| Restaurants | 1 | 1998 | 15 | 0.010 |
Why?
| Food Handling | 1 | 1998 | 51 | 0.010 |
Why?
| Swimming | 1 | 1998 | 48 | 0.010 |
Why?
| Progesterone | 1 | 1979 | 248 | 0.010 |
Why?
| Water Supply | 1 | 1998 | 75 | 0.010 |
Why?
| Disease Transmission, Infectious | 1 | 1998 | 59 | 0.010 |
Why?
| Meat | 1 | 1998 | 92 | 0.010 |
Why?
| Halothane | 1 | 1996 | 6 | 0.010 |
Why?
| Estradiol | 1 | 1979 | 485 | 0.010 |
Why?
| Feces | 1 | 1998 | 400 | 0.010 |
Why?
| Analysis of Variance | 1 | 1999 | 1383 | 0.010 |
Why?
| Population Surveillance | 1 | 1999 | 439 | 0.010 |
Why?
| Ovarian Neoplasms | 1 | 1978 | 415 | 0.010 |
Why?
| Pedigree | 3 | 1978 | 502 | 0.010 |
Why?
| Kidney | 1 | 1996 | 1247 | 0.010 |
Why?
| Aged, 80 and over | 1 | 1999 | 6974 | 0.000 |
Why?
| Nebraska | 2 | 1976 | 7 | 0.000 |
Why?
| New York | 2 | 1976 | 121 | 0.000 |
Why?
| Genes | 1 | 1978 | 237 | 0.000 |
Why?
| Genetic Linkage | 1 | 1978 | 331 | 0.000 |
Why?
| Oncogenic Viruses | 1 | 1976 | 3 | 0.000 |
Why?
| Apocrine Glands | 1 | 1976 | 4 | 0.000 |
Why?
| Genetic Techniques | 1 | 1976 | 63 | 0.000 |
Why?
| Pheochromocytoma | 1 | 1976 | 52 | 0.000 |
Why?
| Klinefelter Syndrome | 1 | 1976 | 51 | 0.000 |
Why?
| Syndrome | 1 | 1976 | 365 | 0.000 |
Why?
| Pregnancy | 2 | 1978 | 5663 | 0.000 |
Why?
| Statistics as Topic | 1 | 1976 | 328 | 0.000 |
Why?
| HLA Antigens | 1 | 1976 | 233 | 0.000 |
Why?
| Sarcoma | 1 | 1976 | 134 | 0.000 |
Why?
| Abnormalities, Multiple | 1 | 1976 | 179 | 0.000 |
Why?
| Skin Diseases | 1 | 1976 | 165 | 0.000 |
Why?
| Thyroid Neoplasms | 1 | 1976 | 269 | 0.000 |
Why?
| Sex Factors | 1 | 1978 | 1898 | 0.000 |
Why?
| Neoplasms | 2 | 1976 | 2241 | 0.000 |
Why?
| Melanoma | 1 | 1976 | 705 | 0.000 |
Why?
| Registries | 1 | 1976 | 1956 | 0.000 |
Why?
| Phenotype | 1 | 1976 | 3078 | 0.000 |
Why?
| Brain Neoplasms | 1 | 1976 | 1031 | 0.000 |
Why?
|
|
Maloney's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|